Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts

BACKGROUND: First Nation populations in Canada have a very low incidence of inflammatory bowel disease (IBD). Based on typical infections in this population, it is plausible that the First Nations react differently to microbial antigens with a different antibody response pattern, which may shed some...

Full description

Bibliographic Details
Published in:Canadian Journal of Gastroenterology
Main Authors: Charles N Bernstein, Hani El-Gabalawy, Michael Sargent, Carol J Landers, Patricia Rawsthorne, Brenda Elias, Stephan R Targan
Format: Article in Journal/Newspaper
Language:English
Published: Canadian Journal of Gastroenterology 2011
Subjects:
Online Access:https://doi.org/10.1155/2011/712350
id fthindawi:oai:hindawi.com:10.1155/2011/712350
record_format openpolar
spelling fthindawi:oai:hindawi.com:10.1155/2011/712350 2023-05-15T16:14:01+02:00 Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts Charles N Bernstein Hani El-Gabalawy Michael Sargent Carol J Landers Patricia Rawsthorne Brenda Elias Stephan R Targan 2011 https://doi.org/10.1155/2011/712350 en eng Canadian Journal of Gastroenterology https://doi.org/10.1155/2011/712350 Copyright © 2011 Hindawi Publishing Corporation. Original Article 2011 fthindawi https://doi.org/10.1155/2011/712350 2019-05-26T05:19:57Z BACKGROUND: First Nation populations in Canada have a very low incidence of inflammatory bowel disease (IBD). Based on typical infections in this population, it is plausible that the First Nations react differently to microbial antigens with a different antibody response pattern, which may shed some light as to why they experience a low rate of IBD.OBJECTIVE: To compare the positivity rates of antibodies known to be associated with IBD in Canadian First Nations compared with a Canadian Caucasian population.METHODS: Subjects with Crohn’s disease, ulcerative colitis (UC), rheumatoid arthritis (RA) (as an immune disease control) and healthy controls without a personal or family history of chronic immune diseases, were enrolled in a cohort study aimed to determine differences between First Nations and Caucasians with IBD or RA. Serum from a random sample of these subjects (n=50 for each of First Nations with RA, First Nations controls, Caucasians with RA, Caucasians with Crohn’s disease, Caucasians with UC and Caucasians controls, and as many First Nations with either Crohn’s disease or UC as could be enrolled) was analyzed in the laboratory for the following antibodies: perinuclear antineutrophil cytoplasmic antibody (pANCA), and four Crohn’s disease-associated antibodies including anti-Saccharomyces cerevisiae, the outer membrane porin C of Escherichia coli, I2 – a fragment of bacterial DNA associated with Pseudomonas fluorescens, and the bacterial flagellin CBir-1. The rates of positive antibody responses and mean titres among positive results were compared.RESULTS: For pANCA, First Nations had a positivity rate of 55% in those with UC, 32% in healthy controls and 48% in those with RA. The pANCA positivity rate was 32% among Caucasians with RA. The rates of the Crohn’s disease-associated antibodies for the First Nations and Caucasians were comparable. Among First Nations, up to one in four healthy controls were positive for any one of the Crohn’s disease-associated antibodies. First Nations had significantly higher pANCA titres in both the UC and RA groups than CaucasiansDISCUSSION: Although First Nation populations experience a low rate of IBD, they are relatively responsive to this particular antibody panel.CONCLUSIONS: The positivity rates of these antibodies in First Nations, despite the low incidence of IBD in this population, suggest that these antibodies are unlikely to be of pathogenetic significance. Article in Journal/Newspaper First Nations Hindawi Publishing Corporation Canada Canadian Journal of Gastroenterology 25 5 269 273
institution Open Polar
collection Hindawi Publishing Corporation
op_collection_id fthindawi
language English
description BACKGROUND: First Nation populations in Canada have a very low incidence of inflammatory bowel disease (IBD). Based on typical infections in this population, it is plausible that the First Nations react differently to microbial antigens with a different antibody response pattern, which may shed some light as to why they experience a low rate of IBD.OBJECTIVE: To compare the positivity rates of antibodies known to be associated with IBD in Canadian First Nations compared with a Canadian Caucasian population.METHODS: Subjects with Crohn’s disease, ulcerative colitis (UC), rheumatoid arthritis (RA) (as an immune disease control) and healthy controls without a personal or family history of chronic immune diseases, were enrolled in a cohort study aimed to determine differences between First Nations and Caucasians with IBD or RA. Serum from a random sample of these subjects (n=50 for each of First Nations with RA, First Nations controls, Caucasians with RA, Caucasians with Crohn’s disease, Caucasians with UC and Caucasians controls, and as many First Nations with either Crohn’s disease or UC as could be enrolled) was analyzed in the laboratory for the following antibodies: perinuclear antineutrophil cytoplasmic antibody (pANCA), and four Crohn’s disease-associated antibodies including anti-Saccharomyces cerevisiae, the outer membrane porin C of Escherichia coli, I2 – a fragment of bacterial DNA associated with Pseudomonas fluorescens, and the bacterial flagellin CBir-1. The rates of positive antibody responses and mean titres among positive results were compared.RESULTS: For pANCA, First Nations had a positivity rate of 55% in those with UC, 32% in healthy controls and 48% in those with RA. The pANCA positivity rate was 32% among Caucasians with RA. The rates of the Crohn’s disease-associated antibodies for the First Nations and Caucasians were comparable. Among First Nations, up to one in four healthy controls were positive for any one of the Crohn’s disease-associated antibodies. First Nations had significantly higher pANCA titres in both the UC and RA groups than CaucasiansDISCUSSION: Although First Nation populations experience a low rate of IBD, they are relatively responsive to this particular antibody panel.CONCLUSIONS: The positivity rates of these antibodies in First Nations, despite the low incidence of IBD in this population, suggest that these antibodies are unlikely to be of pathogenetic significance.
format Article in Journal/Newspaper
author Charles N Bernstein
Hani El-Gabalawy
Michael Sargent
Carol J Landers
Patricia Rawsthorne
Brenda Elias
Stephan R Targan
spellingShingle Charles N Bernstein
Hani El-Gabalawy
Michael Sargent
Carol J Landers
Patricia Rawsthorne
Brenda Elias
Stephan R Targan
Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts
author_facet Charles N Bernstein
Hani El-Gabalawy
Michael Sargent
Carol J Landers
Patricia Rawsthorne
Brenda Elias
Stephan R Targan
author_sort Charles N Bernstein
title Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts
title_short Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts
title_full Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts
title_fullStr Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts
title_full_unstemmed Assessing Inflammatory Bowel Disease-Associated Antibodies in Caucasian and First Nations Cohorts
title_sort assessing inflammatory bowel disease-associated antibodies in caucasian and first nations cohorts
publisher Canadian Journal of Gastroenterology
publishDate 2011
url https://doi.org/10.1155/2011/712350
geographic Canada
geographic_facet Canada
genre First Nations
genre_facet First Nations
op_relation https://doi.org/10.1155/2011/712350
op_rights Copyright © 2011 Hindawi Publishing Corporation.
op_doi https://doi.org/10.1155/2011/712350
container_title Canadian Journal of Gastroenterology
container_volume 25
container_issue 5
container_start_page 269
op_container_end_page 273
_version_ 1765999859785007104